Fig. 1: Outcomes by COO in an independent validation cohort of 68 patients receiving first-line CHOP or R-CHOP. | Blood Cancer Journal

Fig. 1: Outcomes by COO in an independent validation cohort of 68 patients receiving first-line CHOP or R-CHOP.

From: Integrating precision medicine through evaluation of cell of origin in treatment planning for diffuse large B-cell lymphoma

Fig. 1

a PFS by COO per Lymph2Cx, b OS by COO group per Lymph2Cx, c PFS by COO group per gold standard GEP, and d OS by COO per gold standard GEP. CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; COO cell of origin, GEP gene expression profiling, OS overall survival, PFS progression-free survival, R-CHOP rituximab with CHOP, RR relative risk (with 95% confidence interval). Republished with permission of Blood: a journal of the American Society of Hematology, from Scott et al.55; permission conveyed through Copyright Clearance Center, Inc

Back to article page